The University College London recently published an article that focused on a further analysis of the GENERATION-HD1 clinical trial. This analysis co-authored by Professors Sarah Tabrizi and Edward Wild (Huntington’s Disease Centre, UCL Queen Square Institute of Neurology) proposed using the disease-modifying drug tominersen to treat early-stage Huntington’s disease following the early stopping of the GENERATION-HD1 phase 3 trial.

"The early stopping of this trial was devastating for the Huntington's disease community at every level. Now the full and open publication of the results is important, as we will all learn from these data. They will inform new trial designs, dosing regimens, stage of disease to treat, and they are important too for the development of antisense oligonucleotides for gain of function adult neurodegenerative diseases on a wider level." Dr. Sarah Tabrizi

Read the Complete Article